Novartis has for years been developing and producing vaccines, including viral antigens against ISA. It produced the first ISA vaccine in Canada in 1999 and currently has a portfolio of ISA vaccines that are marketed in Canada, the Faroe Islands, Norway and Chile, amounting to more than 200 million fish vaccinated over 10 years.
According to Constantino Siderakis, the marketing and sales manager of the company’s aquaculture business, the new vaccine is a product designed for Chile and corresponds to a second generation of ISA vaccines, which was obtained with a new formulation to increase the efficiency and specific immunity against the virus.
The
